Spots Global Cancer Trial Database for A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Official Title: A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
Study ID: NCT04144517
Study Description
Brief Summary: The primary objective of this study is to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who have previously received anti-PD-(L)1 therapy but who have not achieved a CR.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mural Oncology Investigational Site, Miami, Florida, United States
Mural Oncology Investigational Site, Atlanta, Georgia, United States
Mural Oncology Investigational Site, Minneapolis, Minnesota, United States
Mural Oncology Investigational Site, New York, New York, United States
Mural Oncology Investigational Site, Cleveland, Ohio, United States
Mural Oncology Investigational Site, Austin, Texas, United States
Contact Details
Name: Medical Director
Affiliation: Mural Oncology, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
